Literature DB >> 27387171

An Assessment of the Permeation Enhancer, 1-phenyl-piperazine (PPZ), on Paracellular Flux Across Rat Intestinal Mucosae in Ussing Chambers.

V A Bzik1, D J Brayden2.   

Abstract

PURPOSE: 1-phenyl piperazine (PPZ) emerged from a Caco-2 monolayer screen as having high enhancement potential due to a capacity to increase permeation without significant toxicity. Our aim was to further explore the efficacy and toxicity of PPZ in rat ileal and colonic mucosae in order to assess its true translation potential.
METHODS: Intestinal mucosae were mounted in Ussing chambers and apparent permeability coefficient (Papp) values of [(14)C]-mannitol and FITC-dextran 4 kDa (FD-4) and transepithelial electrical resistance (TEER) values were obtained following apical addition of PPZ (0.6-60 mM). Exposed issues were assessed for toxicity by histopathology and lactate dehydrogenase (LDH) release. Mucosal recovery after exposure was also assessed using TEER readings.
RESULTS: PPZ reversibly increased the Papp of both agents across rat ileal and distal colonic mucosae in concentration-dependent fashion, accompanied by TEER reduction, with acceptable levels of tissue damage. The complex mechanism of tight junction opening was part mediated by myosin light chain kinase, stimulation of transepithelial electrogenic chloride secretion, and involved activation of 5-HT4 receptors.
CONCLUSIONS: PPZ is an efficacious and benign intestinal permeation enhancer in tissue mucosae. However, its active pharmacology suggest that potential for further development in an oral formulation for poorly permeable molecules will be difficult.

Entities:  

Keywords:  Ussing chambers; epithelial tight junctions; intestinal permeation enhancers; oral peptides; phenyl piperazine

Mesh:

Substances:

Year:  2016        PMID: 27387171     DOI: 10.1007/s11095-016-1975-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  35 in total

1.  Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin.

Authors:  Susan B Fowler; Stephen Poon; Roman Muff; Fabrizio Chiti; Christopher M Dobson; Jesús Zurdo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

2.  Membrane transport of drugs in different regions of the intestinal tract of the rat.

Authors:  A L Ungell; S Nylander; S Bergstrand; A Sjöberg; H Lennernäs
Journal:  J Pharm Sci       Date:  1998-03       Impact factor: 3.534

Review 3.  Serotonin and its role in colonic function and in gastrointestinal disorders.

Authors:  Meagan M Costedio; Neil Hyman; Gary M Mawe
Journal:  Dis Colon Rectum       Date:  2007-03       Impact factor: 4.585

4.  Study of serotonin interactions with brush border membrane of rabbit jejunum enterocytes.

Authors:  A I Alcalde; V Sorribas; M J Rodriguez-Yoldi; A Lahuerta
Journal:  Eur J Pharmacol       Date:  2000-09-01       Impact factor: 4.432

5.  Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception.

Authors:  J X Chen; H Pan; T P Rothman; P R Wade; M D Gershon
Journal:  Am J Physiol       Date:  1998-09

6.  Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in vitro.

Authors:  Linda M Feighery; Sean W Cochrane; Teresa Quinn; Alan W Baird; Daniel O'Toole; Sian-Eleri Owens; Diarmuid O'Donoghue; Randall J Mrsny; David J Brayden
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

7.  Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.

Authors:  Romano Di Fabio; Cristiana Griffante; Giuseppe Alvaro; Giorgio Pentassuglia; Domenica A Pizzi; Daniele Donati; Tino Rossi; Giuseppe Guercio; Mario Mattioli; Zadeo Cimarosti; Carla Marchioro; Stefano Provera; Laura Zonzini; Dino Montanari; Sergio Melotto; Philip A Gerrard; David G Trist; Emiliangelo Ratti; Mauro Corsi
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

8.  Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae.

Authors:  Sam Maher; Rory Kennelly; Victoria A Bzik; Alan W Baird; Xuexuan Wang; Desmond Winter; David J Brayden
Journal:  Eur J Pharm Sci       Date:  2009-09-06       Impact factor: 4.384

9.  Luminally released serotonin stimulates colonic motility and accelerates colonic transit in rats.

Authors:  Kiyoshi Tsukamoto; Hajime Ariga; Chris Mantyh; Theodore N Pappas; Hidenori Yanagi; Takehira Yamamura; Toku Takahashi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-04-18       Impact factor: 3.619

10.  Evaluation of alkylmaltosides as intestinal permeation enhancers: comparison between rat intestinal mucosal sheets and Caco-2 monolayers.

Authors:  Signe Beck Petersen; Gavin Nolan; Sam Maher; Ulrik Lytt Rahbek; Mette Guldbrandt; David J Brayden
Journal:  Eur J Pharm Sci       Date:  2012-08-23       Impact factor: 4.384

View more
  3 in total

1.  Investigations of Piperazine Derivatives as Intestinal Permeation Enhancers in Isolated Rat Intestinal Tissue Mucosae.

Authors:  V Stuettgen; D J Brayden
Journal:  AAPS J       Date:  2020-01-27       Impact factor: 4.009

2.  Structure-Function Analysis of Phenylpiperazine Derivatives as Intestinal Permeation Enhancers.

Authors:  Katherine C Fein; Nicholas G Lamson; Kathryn A Whitehead
Journal:  Pharm Res       Date:  2017-04-03       Impact factor: 4.200

3.  The EXTrauterine Environment for Neonatal Development Supports Normal Intestinal Maturation and Development.

Authors:  Heron D Baumgarten; Christina M Wright; Avery C Rossidis; Kendall M Lawrence; Aimee G Kim; Ali Y Mejaddam; Patrick E McGovern; Melissa N Orr; Barbara E Coons; Zoya Butt; Haiying Li; Grace Hwang; Antoneta Radu; Lauren J Brown; Ronald C Rubenstein; William H Peranteau; Marcus Davey; Robert O Heuckeroth; Alan W Flake
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.